Phase 3 studies point to sustained disease control in patients who remain symptomatic despite standard therapies.

Executives on a DealBook Summit task force panel said fear was not the way to build teams capable of navigating difficult ...

GlaxoSmithKline ( ($GB:GSK) ) just unveiled an update. GSK has announced the purchase of 230,000 of its own ordinary shares as part of its ongoing ...

Chronic chikungunya arthritis often mimics rheumatoid arthritis, complicating diagnosis and therapy, and necessitating ...

The Magnum Ice Cream Company, the recent ice cream spin-off from Unilever, rose to the top of the pan-European benchmark, ...

The boss of Britain’s largest drug developer has praised the US as the best place to invest amid fears over the waning appeal ...

DelveInsight’s “Post Traumatic Stress Disorder Market Insights, Epidemiology, and Market Forecast-2034″ report offers an ...

Dame Emma Walmsley, Chief Executive one of Britain's biggest pharmaceutical companies GSK (GlaxoSmithKline), says the company is prioritising the United States for product launches and investment, ...

The Non-Opioid Therapeutics Market is rapidly expanding due to increased demand for safer pain management Non-Opioid Therapeutics Market Non-Opioid Therapeutics Market Dublin, Dec. 11, 2025 (GLOBE ...

Regulators have the authority to penalize false advertising. What they cannot do is enact rules so heavy that legitimate ads cannot run.

Harvey Jones has been hunting for the best shares to buy for his SIPP, and found what he thinks is one in a surprising place.

FIDSON Healthcare Plc has reinforced its commitment to healthcare delivery, corporate governance, and strategic growth ...